Please login to the form below

Not currently logged in
Email:
Password:

Astellas to close US urology research facility

Work at Urogenix, North Carolina site will end by the end of the year

Astellas is to close its Urogenix urology drug discovery facility in North Carolina, with the loss of 13 jobs, by the end of the year.

The Japanese pharma company acquired the facility from Dynogen Pharmaceuticals in 2006 and gave it a particular focus on researching new treatments for lower urinary tract disorder. 

Astellas will transfer its urology research activities to Astellas' Tsukuba Research Center in Japan and said the decision to shut down the unit would allow it to optimise its research and development resource allocation.

6th August 2012

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

AMWA’s President and President Elect talk about the latest offerings
Current AMWA President, Stephen Palmer and President Elect, Lori Alexander discuss AMWA’s offerings: the 2015 salary survey, the Medical Writers Certification, the new online forum called Engage, and how we...
Jennifer Williams Interview: Off-label data communication
Over the past several months I have encountered many questions relating to off-labeling. In this article I am providing the three most asked questions on this topic and the summarized...
Free Thinking: From promise to practice: immuno-oncology in action
...

Infographics